Mon, Nov 24, 2014
A A A
Welcome sandeep.kottawar@wns.com
RSS

Sovereign Wealth Funds Briefing - Categorized | Market

Emergent BioSolutions and Temasek Life Sciences ventures establish joint venture

Posted on 12 August 2010

Temasek Life Science Ventures Pte Ltd (TLV) and Emergent BioSolutions Inc. announced their agreement to form EPIC BIO Pte Ltd, a joint venture to develop, manufacture, and commercialize a multivalent, cross-protective human vaccine to protect against influenza caused by a broad range of circulating H5 influenza strains.
The broad spectrum pandemic flu vaccine is expected to be based on multiple antigens held by TLV and to be delivered as a single vaccine using Emergent’s MVAtor(TM) vaccine delivery platform. Completion of this joint venture is expected in the next few weeks……………………………………….Full Press Release: Source

Podcast Play - Download this article   |   Play - Download Full Briefing   |   Subscribe to the Podcast Feed

 Article link

This post was written by:

VRS - who has written 15247 posts on Opalesque Sovereign Wealth Funds Briefing.


Contact the author

Comments are closed.

banner
November 2014
M T W T F S S
« Oct    
 12
3456789
10111213141516
17181920212223
24252627282930